1 / 12

Optimizing Bioequivalence Studies: Challenges and Solutions

Explore the features, issues, and problems of individual bioequivalence in pharmaceutical sciences. Dive into the behavior of individual bioequivalence and the importance of highly-variable drugs. Learn about the benefits of scaled average bioequivalence over scaled individual bioequivalence for accurate comparisons of means. Understand the constraints on the ratio of geometric means and the practical implications for modified-release formulations. This resource will help you navigate data analysis and statistical methodology for bioequivalence studies effectively.

cheri
Télécharger la présentation

Optimizing Bioequivalence Studies: Challenges and Solutions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SOME FEATURES, ISSUES, AND PROBLEMS OF INDIVIDUAL BIOEQUIVALENCE Laszlo Endrenyi and Laszlo Tothfalusi University of Toronto FDA/CDER Advisory Committee for Pharmaceutical Science November 29, 2001

  2. BEHAVIOR OF INDIVIDUAL BE Individual BE has, in practice, unfavorable properties Acceptance or rejection can be due to random chance alone

  3. HIGHLY-VARIABLE DRUGS Replicate design is recommended Analysis outlined in Guidances: only by scaled individual BE But: scaled average BE is much more effective

  4. For the comparison of means: Scaled average BE [scABE4] is much more effective than scaled individual BE [scIBE4] (smaller consumer and producer risks)

  5. When two criteria are applied jointly, the rate of acceptance is less than that of either component criterion alone; e.g., scaled individual BE [scIBE 4] and GMR=1.25 [GMR_limit] In this case, the joint criterion [GIBE 4_sc] is essentially a GMR criterion

  6. CONSTRAINT ON RATIO OF GEOMETRIC MEANS (GMR)

  7. FIRST SET OF CONCLUSIONSON INDIVIDUAL BIOEQUIVALENCE

  8. BE OF MODIFIED-RELEASE (MR)FORMULATIONS

  9. BE OF MODIFIED-RELEASE (MR)FORMULATIONS

  10. SUBJECT-BY-FORMULATIONINTERACTION (S*F)

  11. DATA ANALYSIS &STATISTICAL METHODOLOGYSuggested projects

More Related